Viggo joined Tevard in 2021 as an associate with over 7 years of experience working on suppressor tRNAs. In his time at Tevard, he has established immortal and primary cell tRNA screening platforms for multiple indications.

Viggo was introduced to suppressor tRNAs in Chris Ahern’s lab at the University of Iowa where he worked on Long QT Syndrome. His time in Iowa resulted in him being named a semifinalist in the 2017 Regeneron Science Talent Search. Viggo continued to work on Long QT at Columbia University in Henry Colecraft’s lab and published in Molecular Therapy.